Newbury Pharmaceuticals brings forward interim report for third quarter 2022/2023 from July 7 to June 14

MFN Publicerad: 13 Jun 2023 17:40

Newbury Pharmaceuticals has previously announced that the interim report for the period September 2022 – May 2023 will be published on July 7. The board has now decided to advance the report date to June 14.

The reason for this decision is that work on the report has gone faster than expected and is available for publication.

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at [email protected] or +46 (0) 40 200 250.

Börskollen

För dig med koll på börsen

Pressmeddelande

Newbury Pharmaceuticals brings forward interim report for third quarter 2022/2023 from July 7 to June 14

Bifogade filer

Nyheter om Newbury Pharmaceuticals

Läses av andra just nu

Om aktien Newbury Pharmaceuticals

Senaste nytt